Finanzas de Dermata Therapeutics Inc (DRMA)DRMADermata Therapeutics Inc

Evaluating the bottom line, Dermata Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -183.89%, provide a clear picture of how effectively DRMA converts its operational activities into shareholder value.

In the context of the broader market, DRMA competes directly with industry leaders such as BYAH and NXTS. With a market capitalization of $3.87M, it holds a significant position in the sector. When comparing efficiency, DRMA's gross margin of N/A stands against BYAH's 96.36% and NXTS's N/A. Such benchmarking helps identify whether Dermata Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Dermata Therapeutics has shown a consistent trend of financial losses, with a net income loss of $2.97 million in Q2 2026, widening from a loss of $1.70 million in Q2 2025. The company has also reported a negative EPS of -0.74 for Q2 2026, indicating ongoing financial challenges.